Epstein-Barr Virus Infections: all 164 studies

Page 2 of 2. Open to participants first (57), then studies with results posted, then the rest; newest registration first within each.

• Inflammation and Co-Infections in D²EFTWithdrawnNCT04183738Phase 4
• PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBVStatus unknownNCT04084626Phase 3
• EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR)Active, not recruitingNCT04072107Phase 2
• Serial Epstein-Barr Virus DNA Surveillance in Nasopharyngeal Carcinoma PatientsActive, not recruitingNCT03855020
• A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive MalignanciesStatus unknownNCT03789617Phase 1/2
• Epstein-Barr Virus Suppression in Chronic Obstructive Pulmonary Disease (EViSCO): a Phase 2 Randomised Control TrialTerminatedNCT03699904Phase 2
• Comparison of Technics for Determination of Epstein-Barr Virus Serological DiagnosisCompletedNCT03650231
• Early Detection of Epstein-Barr Virus Related Disease.CompletedNCT03546101
• Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNATerminatedNCT03544099Phase 2
• Chidamide for Patients With Recurrent and Metastatic Epstein-Barr Virus (EBV)-Associated Solid TumorsStatus unknownNCT03494634Phase 2
• Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell TransplantationActive, not recruitingNCT03475212Phase 1/2
• Immunodeficiency for Severe Epstein-Barr Virus InfectionCompletedNCT03374566
• Methyl-qPCR : a New Predictive Marker for Epstein-Barr Virus-associated Lymphoproliferations During Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT03343834Not applicable
• Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic InfectionsTerminatedNCT03159364Phase 1/2
• Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)CompletedNCT02973113Phase 1
• ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following RadiotherapyTerminatedNCT02874651Phase 2
• Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or MalignanciesNo longer availableNCT02822495
• A Retrospective Chart Review Study of Gene-Eden-VIR/NovirinCompletedNCT02715752
• Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell LymphomaCompletedNCT02670616Phase 2
• L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic LymphohistiocytosisStatus unknownNCT02631109Phase 3
• A Study of the Safety and Efficacy of EBV Specific T-cell LinesCompletedNCT02580539Phase 1/2
• Mental Training for CFS Following EBV Infection in AdolescentsCompletedNCT02499302Not applicable
• A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNATerminatedNCT02363400Phase 3
• Chronic Fatigue Following Acute Epstein-Barr Virus Infection in AdolescentsCompletedNCT02335437
• Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNAActive, not recruitingNCT02135042Phase 2/3
• Prospective Nasopharyngeal Carcinoma Screening Using Plasma Epstein-Barr Virus DNA AnalysisStatus unknownNCT02063399
• Epstein-Barr Virus Status in Diffuse Large B Cell LymphomaCompletedNCT02060435
• Reproducibility and Reliability of Epstein-Barr Virus (EBV) DNA/RNA Measures in Nasopharyngeal SwabsStatus unknownNCT01972815
• Cytotoxic T Cells to Treat Relapsed EBV-positive LymphomaCompletedNCT01956084Phase 1
• Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)No longer availableNCT01945619
• A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal CarcinomaCompletedNCT01800071Phase 1
• Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins LymphomaTerminatedNCT01636388Phase 2
• Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMVCompletedNCT01535885Phase 1
• Administration of Donor T Cells With the Caspase-9 Suicide GeneActive, not recruitingNCT01494103Phase 1
• Modified Vaccinia Ankara (MVA) Vaccine StudyCompletedNCT01256853Phase 1
• The Prevelance Rate of Human Cytomegalovirus (HCMV), Epstein-Barr Virus (EBV) and Human Herpes Virus (HHV-6) in a Saliva of the Patient With PeriodantitisStatus unknownNCT01248598
• Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related CancerCompletedNCT01147991Phase 1
• Expression of S100A2 and Trefoil Factor Family Members in Epstein-Barr Virus Related Gastric CancerStatus unknownNCT01100814
• Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional TherapyCompletedNCT01094405Phase 2
• Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE)CompletedNCT01070797Phase 1
• Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative DisordersTerminatedNCT00992732Phase 2
• EBV Infection as a Risk Factor for PTLD in Pediatric and Adult Renal Transplant RecipientsCompletedNCT00963248
• Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T LymphocytesCompletedNCT00953420Phase 2
• Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive LymphomasCompletedNCT00779337Phase 1
• Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL)CompletedNCT00711035Phase 1/2
• Administration of Epstein Barr Virus - Specific Cytotoxic T-Lymphocytes to Metastatic EBV-Positive Nasopharygneal CancerCompletedNCT00706316Phase 1
• Surveillance Study of Viral Infections Following Lung TransplantationCompletedNCT00701922
• Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)CompletedNCT00478465Phase 1/2
• Epstein-Barr Virus as a Possible Cause for Chronic Fatigue SyndromeCompletedNCT00433355
• Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal CarcinomaCompletedNCT00431210Phase 1
• Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals' EBV (Epstein Barr Virus) Vaccine (268664).CompletedNCT00430534Phase 2
• Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive CancerWithdrawnNCT00387530Phase 2
• Prevalence of Cytomegalovirus, Epstein Barr Virus and Human Herpes 6 Virus in Inflammatory Bowel DiseaseCompletedNCT00222378
• Positron Emission Tomography Scanning and Epstein-Barr Virus DNA Levels in the Staging and Follow-up of Nasopharyngeal Carcinoma.CompletedNCT00188253
• EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC)CompletedNCT00078546Phase 1
• Protein Studies of the Epstein-Barr Virus in Ethnically Diverse PopulationsCompletedNCT00070785
• Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow GraftsCompletedNCT00058812Phase 1
• Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGELCompletedNCT00058617Phase 1
• Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs).CompletedNCT00058604Phase 1
• Treating Severe Chronic Epstein-Barr Virus (EBV) Infection With EBV Specific Cytotoxic T Lymphocytes (CTLs)CompletedNCT00058591Phase 1
• Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's LymphomaStatus unknownNCT00006100Phase 1
• Effects of Long-Term Treatment With Valaciclovir (Valtrex) on Epstein-Barr VirusCompletedNCT00005924
• Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone TransplantationCompletedNCT00005606Phase 2
• Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ TransplantsWithdrawnNCT00002956Phase 1

← Epstein-Barr Virus Infections overview